Augurex Life Sciences Corp.

Augurex is a biotechnology company that is focused on developing biomarker blood tests that transform patient clinical management for better disease outcomes. Extracellular 14-3-3? (eta) protein represents Augurex’s first commercialized blood test, JOINTstatâ„¢ for the diagnosis and management of rheumatoid arthritis (RA) and also serves as a drug target for the personalized treatment of RA. A novel 14-3-3?-centric autoimmune portfolio has emerged from this transformational biomarker, forming the basis of Augurex pipeline research.